Abstract
Post-transplant diabetes mellitus (PTDM) is a frequent and relevant complication after renal transplantation: it affects 20–30% of renal transplant recipients and increases the risk for cardiovascular and infectious events. Thus, understanding pathogenesis of PTDM would help limiting its consequences. In this review, we analyse novel aspects of PTDM, based on studies of the last decade, such as the clinical evolution of PTDM, early and late, the reversibility rate, diagnostic criteria, risk factors, including pre-transplant metabolic syndrome and insulin resistance (IR) and the interaction between these factors and immunosuppressive medications. Also, we discuss novel pathogenic factors, in particular the role of β-cell function in an environment of IR and common pathways between pre-existing cell damage and tacrolimus-induced toxicity. The relevant role of prediabetes in the pathogenesis of PTDM and cardiovascular disease is also addressed. Finally, current evidence on PTDM treatment is discussed.
References
1.
Davidson
JA
, Wilkinson
A
. New-onset diabetes after transplantation 2003 International consensus guidelines: an endocrinologist’s view
. Diabetes Care
. 2004 Mar
;27
(3
):805
–12
. .2.
Hagen
M
, Hjelmesaeth
J
, Jenssen
T
, Morkrid
L
, Hartmann
A
. A 6-year prospective study on new onset diabetes mellitus, insulin release and insulin sensitivity in renal transplant recipients
. Nephrol Dial Transplant
. 2003 Oct
;18
(10
):2154
–9
. .3.
Seoane-Pillado
MT
, Pita-Fernández
S
, Valdés-Cañedo
F
, Seijo-Bestilleiro
R
, Pértega-Díaz
S
, Fernández-Rivera
C
, et al. Incidence of cardiovascular events and associated risk factors in kidney transplant patients: a competing risks survival analysis
. BMC Cardiovasc Disord
. 2017 Mar 7
;17
(1
):72
. .4.
American Diabetes Association
. Diagnosis and classification of diabetes mellitus
. Diabetes Care
. 2005
;28
(Suppl 1
):S37
–42
. .5.
Chakkera
HA
, Weil
EJ
, Castro
J
, Heilman
RL
, Reddy
KS
, Mazur
MJ
, et al. Hyperglycemia during the immediate period after kidney transplantation
. Clin J Am Soc Nephrol
. 2009
;4
(4
):853
–9
. .6.
Chakkera
HA
, Weil
EJ
, Castro
J
, Heilman
RL
, Reddy
KS
, Mazur
MJ
, et al. Hyperglycemia during the immediate period after kidney transplantation
. Clin J Am Soc Nephrol
. 2009 Apr
;4
(4
):853
–9
. .7.
American Diabetes Association
. 2. Classifications and diagnosis of diabetes: standards of medical care in diabetes: 2019
. Diabetes Care
. 2019 Jan
;42
(Suppl 1
):S13
–28
. .8.
Eide
IA
, Halden
TA
, Hartmann
A
, Åsberg
A
, Dahle
DO
, Reisæter
AV
, et al. Limitations of hemoglobin A1c for the diagnosis of posttransplant diabetes mellitus
. Transplantation
. 2015 Mar
;99
(3
):629
–35
. .9.
Fishbane
S
, Spinowitz
B
. Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018
. Am J Kidney Dis
. 2018 Mar
;71
(3
):423
–35
. .10.
EL Okel
AZ
, El-Arbagy
AR
, Yassein
YS
, Khodir
SZ
, El Sayed Kasem
H
. Effect of erythropoietin treatment on hemoglobin A1c levels in diabetic patients with chronic kidney disease
. J Egypt Soc Nephrol Transplant
. 2019
;19
:86
–94
.11.
Ng
JM
, Cooke
M
, Bhandari
S
, Atkin
SL
, Kilpatrick
ES
. The effect of iron and erythropoietin treatment on the A1C of patients with diabetes and chronic kidney disease
. Diabetes Care
. 2010 Nov
;33
(11
):2310
–3
. .12.
Ussif
AM
, Åsberg
A
, Halden
TAS
, Nordheim
E
, Hartmann
A
, Jenssen
T
. Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation
. BMC Nephrol
. 2019 Jan 10
;20
(1
):12
. .13.
Porrini
EL
, Díaz
JM
, Moreso
F
, Delgado Mallén
PI
, Silva Torres
I
, Ibernon
M
, et al. Clinical evolution of post-transplant diabetes mellitus
. Nephrol Dial Transplant
. 2016 Mar
;31
(3
):495
–505
. .14.
Caillard
S
, Eprinchard
L
, Perrin
P
, Braun
L
, Heibel
F
, Moreau
F
, et al. Incidence and risk factors of glucose metabolism disorders in kidney transplant recipients: role of systematic screening by oral glucose tolerance test
. Transplantation
. 2011 Apr 15
;91
(7
):757
–64
. .15.
Cosio
FG
, Kudva
Y
, van der Velde
M
, Larson
TS
, Textor
SC
, Griffin
MD
, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation
. Kidney Int
. 2005 Jun
;67
(6
):2415
–21
. .16.
Lv
C
, Chen
M
, Xu
M
, Xu
G
, Zhang
Y
, He
S
, et al. Influencing factors of new-onset diabetes after a renal transplant and their effects on complications and survival rate
. PLoS One
. 2014 Jun 9
;9
(6
):e99406
. .17.
Al-Ghareeb
SM
, El-Agroudy
AE
, Al Arrayed
SM
, Al Arrayed
A
, Alhellow
HA
. Risk factors and outcomes of new-onset diabetes after transplant: single-centre experience
. Exp Clin Transplant
. 2012 Oct
;10
(5
):458
–65
. .18.
Sarno
G
, Muscogiuri
G
, De Rosa
P
. New-onset diabetes after kidney transplantation: prevalence, risk factors, and management
. Transplantation
. 2012 Jun 27
;93
(12
):1189
–95
. .19.
Yeh
H
, Lin
C
, Li
YR
, Yen
CL
, Lee
CC
, Chen
JS
, et al. Temporal trends of incident diabetes mellitus and subsequent outcomes in patients receiving kidney transplantation: a national cohort study in Taiwan
. Diabetol Metab Syndr
. 2020 Apr 28
;12
:34
. .20.
Khong
MJ
, Chong
CP
. Prevention and management of new-onset diabetes mellitus in kidney transplantation
. Neth J Med
. 2014 Apr
;72
(3
):127
–34
.21.
Yates
CJ
, Fourlanos
S
, Hjelmesaeth
J
, Colman
PG
, Cohney
SJ
. New-onset diabetes after kidney transplantation-changes and challenges
. Am J Transplant
. 2012 Apr
;12
(4
):820
–8
. .22.
Al Saran
K
, Elsayed
S
, Sabry
A
, Hamada
M
. Obesity and metabolic syndrome in hemodialysis patients: single center experience
. Saudi J Kidney Dis Transpl
. 2011
;22
(6
):1193
–8
.23.
Jalalzadeh
M
, Mohammadi
R
, Mirzamohammadi
F
, Ghadiani
MH
. Prevalence of metabolic syndrome in a hemodialysis population
. Iran J Kidney Dis
. 2011
;5
(4
):248
–54
.24.
Tu
SF
, Chou
YC
, Sun
CA
, Hsueh
SC
, Yang
T
. The prevalence of metabolic syndrome and factors associated with quality of dialysis among hemodialysis patients in Southern Taiwan
. Glob J Health Sci
. 2012
;4
(5
):53
–62
. .25.
Bayer
ND
, Cochetti
PT
, Anil Kumar
MS
, Teal
V
, Huan
Y
, Doria
C
, et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation
. Transplantation
. 2010 Oct 27
;90
(8
):861
–6
. .26.
de Lucena
DD
, de Sá
JR
, Medina-Pestana
JO
, Rangel
ÉB
. Modifiable variables are major risk factors for posttransplant diabetes mellitus in a time-dependent manner in kidney transplant: an observational cohort study
. J Diabetes Res
. 2020 Mar 18
;2020
:20201938703
. .27.
Bergrem
HA
, Valderhaug
TG
, Hartmann
A
, Hjelmesaeth
J
, Leivestad
T
, Bergrem
H
, et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy
. Clin J Am Soc Nephrol
. 2010 Apr
;5
(4
):616
–22
. .28.
Bonet
J
, Martinez-Castelao
A
, Bayés
B
. Metabolic syndrome in hemodialysis patients as a risk factor for new-onset diabetes mellitus after renal transplant: a prospective observational study
. Diabetes Metab Syndr Obes
. 2013 Sep 18
;6
:339
–46
. .29.
Sharif
A
, Baboolal
K
. Risk factors for new-onset diabetes after kidney transplantation
. Nat Rev Nephrol
. 2010 Jul
;6
(7
):415
–23
. .30.
Pham
PT
, Pham
PM
, Pham
SV
, Pham
PA
, Pham
PC
. New onset diabetes after transplantation (NODAT): an overview
. Diabetes Metab Syndr Obes
. 2011
;4
:175
–86
. .31.
Vincenti
F
, Charpentier
B
, Vanrenterghem
Y
, Rostaing
L
, Bresnahan
B
, Darji
P
, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)
. Am J Transplant
. 2010
;10
(3
):535
–46
. .32.
Durrbach
A
, Pestana
JM
, Pearson
T
, Vincenti
F
, Garcia
VD
, Campistol
J
, et al. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study)
. Am J Transplant
. 2010
;10
(3
):547
–57
. .33.
Wen
X
, Casey
MJ
, Santos
AH
, Hartzema
A
, Womer
KL
. Comparison of utilization and clinical outcomes for belatacept- and tacrolimus-based immunosuppression in renal transplant recipients
. Am J Transplant
. 2016 Nov
;16
(11
):3202
–11
. .34.
DeFronzo
RA
. Pathogenesis of type 2 diabetes mellitus
. Med Clin North Am
. 2004 Jul
;88
(4
):787
–835.ix
. .35.
Leahy
JL
. Pathogenesis of type 2 diabetes mellitus
. Arch Med Res
. 2005 May–Jun
;36
(3
):197
–209
. .36.
Reaven
GM
. Banting lecture 1988. Role of insulin resistance in human disease
. Diabetes
. 1988
;37
(12
):1595
–607
. .37.
Kahn
CR
. Insulin resistance, insulin sensitivity, and insulin unresponsiveness: a necessary distinction
. Metabolism
. 1978
;27
:1893
–902
.38.
David
M
, Nathan
MD
. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus
. N Engl J Med
. 2002
;347
(17
):1342
–9
. .39.
Andrew
M
. Freeman; nicholas pennings. Insulin resistance
. Treasure Island, FL
: StatPearls Publishing
; 2020 Jan
.40.
Roberts
CK
, Hevener
AL
, Barnard
RJ
. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training
. Compr Physiol
. 2013 Jan
;3
(1
):1
–58
. .41.
Hornum
M
, Jørgensen
KA
, Hansen
JM
, Nielsen
FT
, Christensen
KB
, Mathiesen
ER
, et al. New-onset diabetes mellitus after kidney transplantation in Denmark
. Clin J Am Soc Nephrol
. 2010 Apr
;5
(4
):709
–16
. .42.
Jørgensen
MB
, Hornum
M
, van Hall
G
, Bistrup
C
, Hansen
JM
, Mathiesen
ER
, et al. The impact of kidney transplantation on insulin sensitivity
. Transpl Int
. 2017 Mar
[cited 2019 Jun 11];30
(3
):295
–304
. .];43.
Ferrannini
E
, Gastaldelli
A
, Miyazaki
Y
, Matsuda
M
, Mari
A
, DeFronzo
RA
. Beta cell function in subjects spanning the range from normal glucose tolerance to overt diabetes mellitus: a new analysis
. J Clin Endocrinol Metab
. 2005 Jan
;90
(1
):493
–500
.44.
DeFronzo
RA
, Abdul-Ghani
MA
. Preservation of β-cell function: the key to diabetes prevention
. J Clin Endocrinol Metab
. 2011 Aug
;96
(8
):2354
–66
.45.
DeFronzo
RA
, Alvestrand
A
, Smith
D
, Hendler
R
, Hendler
E
, Wahren
J
. Insulin resistance in uremia
. J Clin Invest
. 1981
;67
(2
):563
–8
. .46.
Ford
ES
, Li
C
, Sattar
N
. Metabolic syndrome and incident diabetes: current state of the evidence
. Diabetes Care
. 2008 Sep
;31
(9
):1898
–904
. .47.
Cerf
ME
. Beta cell dysfunction and insulin resistance
. Front Endocrinol
. 2013 Mar 27
;4
:37
. .48.
Fu
Z
, Gilbert
ER
, Liu
D
. Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes
. Curr Diabetes Rev
. 2013 Jan 1
;9
(1
):25
–53
. .49.
Leahy
JL
. β cell dysfunction with chronic hyperglycaemia in type 2 diabetes: the “overworked β cells” hypothesis
. Diabetes Rev
. 1996
;4
:298
–319
.50.
Butler
AE
, Janson
J
, Bonner-Weir
S
, Ritzel
R
, Rizza
RA
, Butler
PC
. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes
. Diabetes
. 2003 Jan
;52
(1
):102
–10
. .51.
Yoon
KH
, Ko
SH
, Cho
JH
, Lee
JM
, Ahn
YB
, Song
KH
, et al. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea
. J Clin Endocrinol Metab
. 2003 May
;88
(5
):2300
–8
. .52.
Rahier
J
, Guiot
Y
, Goebbels
RM
, Sempoux
C
, Henquin
JC
. Pancreatic beta-cell mass in European subjects with type 2 diabetes
. Diabetes Obes Metab
. 2008 Nov
;10
(Suppl 4
):32
–42
. .53.
Talchai
C
, Xuan
S
, Lin
HV
, Sussel
L
, Accili
D
. Pancreatic β cell dedifferentiation as a mechanism of diabetic β cell failure
. Cell
. 2012 Sep 14
;150
(6
):1223
–34
. .54.
Bensellam
M
, Jonas
JC
, Laybutt
DR
. Mechanisms of β-cell dedifferentiation in diabetes: recent findings and future research directions
. J Endocrinol
. 2018 Feb
;236
(2
):R109
–43
.55.
Wang
H
, Brun
T
, Kataoka
K
, Sharma
AJ
, Wollheim
CB
. MAFA controls genes implicated in insulin biosynthesis and secretion
. Diabetologia
. 2007 Feb
;50
(2
):348
–58
. .56.
Kaneto
H
, Miyatsuka
T
, Kawamori
D
, Yamamoto
K
, Kato
K
, Shiraiwa
T
, et al. PDX-1 and MafA play a crucial role in pancreatic beta-cell differentiation and maintenance of mature beta-cell function
. Endocr J
. 2008 May
;55
(2
):235
–52
. .57.
Zhang
C
, Moriguchi
T
, Kajihara
M
, Esaki
R
, Harada
A
, Shimohata
H
, et al. MafA is a key regulator of glucose-stimulated insulin secretion
. Mol Cell Biol
. 2005 Jun
;25
(12
):4969
–76
. .58.
Kitamura
T
. The role of FOXO1 in β-cell failure and type 2 diabetes mellitus
. Nat Rev Endocrinol
. 2013 Oct
;9
(10
):615
–23
. .59.
Guo
S
, Dai
C
, Guo
M
, Taylor
B
, Harmon
JS
, Sander
M
, et al. Inactivation of specific β cell transcription factors in type 2 diabetes
. J Clin Invest
. 2013 Aug
;123
(8
):3305
–16
. .60.
Wang
Z
, York
NW
, Nichols
CG
, Remedi
MS
. Pancreatic β cell dedifferentiation in diabetes and redifferentiation following insulin therapy
. Cell Metab
. 2014 May 6
;19
(5
):872
–82
. .61.
Spijker
HS
, Ravelli
RB
, Mommaas-Kienhuis
AM
, van Apeldoorn
AA
, Engelse
MA
, Zaldumbide
A
, et al. Conversion of mature human β-cells into glucagon-producing α-cells
. Diabetes
. 2013 Jul
;62
(7
):2471
–80
. .62.
Porrini
E
, Delgado
P
, Alvarez
A
, Cobo
M
, Pérez
L
, González-Posada
JM
, et al. The combined effect of pre-transplant triglyceride levels and the type of calcineurin inhibitor in predicting the risk of new onset diabetes after renal transplantation
. Nephrol Dial Transplant
. 2008 Apr
;23
(4
):1436
–41
. .63.
Redmon
JB
, Olson
LK
, Armstrong
MB
, Greene
MJ
, Robertson
RP
. Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells
. J Clin Invest
. 1996 Dec 15
;98
(12
):2786
–93
. .64.
Hernández-Fisac
I
, Pizarro-Delgado
J
, Calle
C
, Marques
M
, Sánchez
A
, Barrientos
A
, et al. Tacrolimus-induced diabetes in rats courses with suppressed insulin gene expression in pancreatic islets
. Am J Transplant
. 2007 Nov
;7
(11
):2455
–62
. .65.
Li
QY
, Li
F
, Sun
JH
, Chi
YY
, Yin
HS
, Liu
SQ
, et al. Mechanisms of diabetes mellitus induced with FK506 in SD rats models
. Immunopharmacol Immunotoxicol
. 2009
;31
(4
):675
–81
. .66.
Morris
R
. Cyclosporin A, FK506, and rapamycin: binding to immunophilins and biological action
. Chem Immunol
. 1994 Dec
;59
(6
):128
–55
.67.
Rodriguez-Rodriguez
AE
, Triñanes
J
, Velazquez-Garcia
S
, Porrini
E
, Vega Prieto
MJ
, Diez Fuentes
ML
, et al. The higher diabetogenic risk of tacrolimus depends on pre-existing insulin resistance. A study in obese and lean Zucker rats
. Am J Transplant
. 2013 Jul
;13
(7
):1665
–75
. .68.
Triñanes
J
, Rodriguez-Rodriguez
AE
, Brito-Casillas
Y
, Wagner
A
, De Vries
APJ
, Cuesto
G
, et al. Deciphering tacrolimus-induced toxicity in pancreatic β cells
. Am J Transplant
. 2017 Nov
;17
(11
):2829
–40
. .69.
Wissing
KM
, Abramowicz
D
, Weekers
L
, Budde
K
, Rath
T
, Witzke
O
, et al. Prospective randomized study of conversion from tacrolimus to cyclosporine A to improve glucose metabolism in patients with posttransplant diabetes mellitus after renal transplantation
. Am J Transplant
. 2018 Jul
;18
(7
):1726
–34
. .70.
Ghisdal
L
, Bouchta
NB
, Broeders
N
, Crenier
L
, Hoang
AD
, Abramowicz
D
, et al. Conversion from tacrolimus to cyclosporine A for new-onset diabetes after transplantation: a single-centre experience in renal transplanted patients and review of the literature
. Transpl Int
. 2008 Feb
;21
(2
):146
–51
. .71.
Aghdasi
B
, Ye
K
, Resnick
A
, Huang
A
, Ha
HC
, Guo
X
, et al. FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle
. Proc Natl Acad Sci U S A
. 2001 Feb 27
;98
(5
):2425
–30
. .72.
Wang
T
, Li
BY
, Danielson
PD
, Shah
PC
, Rockwell
S
, Lechleider
RJ
, et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors
. Cell
. 1996 Aug 9
;86
(3
):435
–44
. .73.
Yao
D
, Doré
JJ
Jr, Leof
EB
. FKBP12 is a negative regulator of transforming growth factor-beta receptor internalization
. J Biol Chem
. 2000 Apr 28
;275
(17
):13149
–54
. .74.
Santulli
G
, Pagano
G
, Sardu
C
, Xie
W
, Reiken
S
, D’Ascia
SL
, et al. Calcium release channel RyR2 regulates insulin release and glucose homeostasis
. J Clin Invest
. 2015 May
;125
(11
):4316
–78
. .75.
Rodriguez-Rodriguez
AE
, Donate-Correa
J
, Rovira
J
, Cuesto
G
, Luis-Ravelo
D
, Fernandes
MX
, et al. Inhibition of the mTOR pathway: a new mechanism of β cell toxicity induced by tacrolimus
. Am J Transplant
. 2019 Dec
;19
(12
):3240
–9
.76.
Triñanes
J
, Ten Dijke
P
, Groen
N
, Hanegraaf
M
, Porrini
E
, Rodriguez-Rodriguez
AE
, et al. Tacrolimus-Induced BMP/SMAD signaling associates with metabolic stress-activated FOXO1 to trigger β-cell failure
. Diabetes
. 2020 Feb
;69
(2
):193
–204
. .77.
Midtvedt
K
, Hartmann
A
, Hjelmesaeth
J
, Lund
K
, Bjerkely
BL
. Insulin resistance is a common denominator of post-transplant diabetes mellitus and impaired glucose tolerance in renal transplant recipients
. Nephrol Dial Transplant
. 1998
;13
(2
):427
–31
. .78.
Ekstrand
AV
, Eriksson
JG
, Grönhagen-Riska
C
, Ahonen
PJ
, Groop
LC
. Insulin resistance and insulin deficiency in the pathogenesis of posttransplantation diabetes in man
. Transplantation
. 1992
;53
(3
):563
–9
. .79.
Oterdoom
LH
, de Vries
AP
, Gansevoort
RT
, van Son
WJ
, van der Heide
JJ
, Ploeg
RJ
, et al. Determinants of insulin resistance in renal transplant recipients
. Transplantation
. 2007
;83
(1
):29
–35
. .80.
Christiansen
E
, Andersen
HB
, Rasmussen
K
, Christensen
NJ
, Olgaard
K
, Kirkegaard
P
, et al. Pancreatic beta-cell function and glucose metabolism in human segmental pancreas and kidney transplantation
. Am J Physiol
. 1993
;264
(3 Pt 1
):E441
–9
. .81.
Markell
M
. New-onset diabetes mellitus in transplant patients: pathogenesis, complications and management
. Am J Kidney Dis
. 2004
;6
:953
–65
.82.
Ozbay
LA
, Møller
N
, Juhl
C
, Bjerre
M
, Carstens
J
, Rungby
J
, et al. The impact of calcineurin inhibitors on insulin sensitivity and insulin secretion: a randomized crossover trial in uraemic patients
. Diabet Med
. 2012 Dec
;29
(12
):e440
–4
. .83.
Chakkera
HA
, Kudva
Y
, Kaplan
B
. Calcineurin inhibitors: pharmacologic mechanisms impacting both insulin resistance and insulin secretion leading to glucose dysregulation and diabetes mellitus
. Clin Pharmacol Ther
. 2017 Jan
;101
(1
):114
–20
. .84.
Lamming
DW
, Ye
L
, Katajisto
P
, Goncalves
MD
, Saitoh
M
, Stevens
DM
, et al. Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity
. Science
. 2012
;335
(6076
):1638
–43
. .85.
Deblon
N
, Bourgoin
L
, Veyrat-Durebex
C
, Peyrou
M
, Vinciguerra
M
, Caillon
A
, et al. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats
. Br J Pharmacol
. 2012
;165
(7
):2325
–40
. .86.
Cosio
FG
, Kudva
Y
, van der Velde
M
, Larson
TS
, Textor
SC
, Griffin
MD
, et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation
. Kidney Int
. 2005
;67
(6
):2415
–21
. .87.
Kasiske
BL
, Snyder
JJ
, Gilbertson
D
, Matas
AJ
. Diabetes mellitus after kidney transplantation in the United States
. Am J Transplant
. 2003
;3
(2
):178
–85
. .88.
Yeh
H
, Lin
C
, Li
YR
, Yen
CL
, Lee
CC
, Chen
JS
, et al. Temporal trends of incident diabetes mellitus and subsequent outcomes in patients receiving kidney transplantation: a national cohort study in Taiwan
. Diabetol Metab Syndr
. 2020 Apr 28
;12
:34
. .89.
Porrini
E
, Díaz
JM
, Moreso
F
, Lauzurrica
R
, Ibernon
M
, Torres
IS
, et al. Prediabetes is a risk factor for cardiovascular disease following renal transplantation
. Kidney Int
. 2019 Dec 1
[cited 2020 Mar 25];96
(6
):1374
–80
. .90.
Scappaticcio
L
, Maiorino
MI
, Bellastella
G
, Giugliano
D
, Esposito
K
. Insights into the relationships between diabetes, prediabetes, and cancer
. Endocrine
. 2017 May
;56
(2
):231
–9
. .91.
Gallagher
EJ
, LeRoith
D
. Obesity and diabetes: the increased risk of cancer and cancer-related mortality
. Physiol Rev
. 2015 Jul
;95
(3
):727
–48
. .92.
Cignarelli
A
, Genchi
VA
, Caruso
I
, Natalicchio
A
, Perrini
S
, Laviola
L
, et al. Diabetes and cancer: pathophysiological fundamentals of a “dangerous affair”
. Diabetes Res Clin Pract
. 2018 Sep
;143
:378
–88
. .93.
Torres
A
, Hernández
D
, Moreso
F
, Serón
D
, Burgos
MD
, Pallardó
LM
, et al. Randomized controlled trial assessing the impact of tacrolimus versus cyclosporine on the incidence of posttransplant diabetes mellitus
. Kidney Int Rep
. 2018 Jul 11
;3
(6
):1304
–15
. .94.
Knowler
WC
, Barrett-Connor
E
, Fowler
SE
, Hamman
RF
, Lachin
JM
, Walker
EA
, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (DPP study)
. N Engl J Med
. 2002 Feb 7
;346
(6
):393
–403
.95.
Pan
XR
, Li
GW
, Hu
YH
, Wang
JX
, Yang
WY
, An
ZX
, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study
. Diabetes Care
. 1997 Apr
;20
(4
):537
–44
.96.
Tuomilehto
J
, Lindström
J
, Eriksson
JG
, Valle
TT
, Hämäläinen
H
, Ilanne-Parikka
P
, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
. N Engl J Med
. 2001 May
;344
(18
):1343
–50
. .97.
Sharif
A
, Hecking
M
, De Vries
AP
, Porrini
E
, Hornum
M
, Rasoul-Rockenschaub
S
, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions
. Am J Transplant
. 2014
;14
(9
):1992
–2000
. .98.
Hecking
M
, Haidinger
M
, Döller
D
, Werzowa
J
, Tura
A
, Zhang
J
, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation
. J Am Soc Nephrol
. 2012 Apr
;23
(4
):739
–49
. .99.
Werzowa
JM
, Säemann
MD
, Mohl
A
, Bergmann
M
, Kaltenecker
CC
, Brozek
W
, et al. A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation
. PLoS One
. 2018 Mar 1
;13
(3
):e0193569
. .100.
Strøm Halden
TA
, Åsberg
A
, Vik
K
, Hartmann
A
, Jenssen
T
. Short-term efficacy and safety of sitagliptin treatment in long-term stable renal recipients with new-onset diabetes after transplantation
. Nephrol Dial Transplant
. 2014 Apr
[cited 2019 Nov 5];29
(4
):926
–33
. .101.
Werzowa
J
, Hecking
M
, Haidinger
M
, Lechner
F
, Döller
D
, Pacini
G
, et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial
. Transplantation
. 2013
;95
(3
):456
–62
. .102.
Haidinger
M
, Werzowa
J
, Hecking
M
, Antlanger
M
, Stemer
G
, Pleiner
J
, et al. Efficacy and safety of vildagliptin in new-onset diabetes after kidney transplantation: a randomized, double-blind, placebo-controlled trial
. Am J Transplant
. 2014 Jan
;14
(1
):115
–23
. .103.
Halden
TA
, Egeland
EJ
, Åsberg
A
, Hartmann
A
, Midtvedt
K
, Khiabani
HZ
, et al. GLP-1 restores altered insulin and glucagon secretion in posttransplantation diabetes
. Diabetes Care
. 2016 Apr
;39
(4
):617
–24
. .104.
Pinelli
NR
, Patel
A
, Salinitri
FD
. Coadministration of liraglutide with tacrolimus in kidney transplant recipients: a case series
. Diabetes Care
. 2013
:36
(10
);e171
–2
.105.
Strøm Halden
TA
, Kvitne
KE
, Midtvedt
K
, Rajakumar
L
, Robertsen
I
, Brox
J
, et al. Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus
. Diabetes Care
. 2019 Jun 1
;42
(6
):1067
–74
.106.
Schwaiger
E
, Burghart
L
, Signorini
L
, Ristl
R
, Kopecky
C
, Tura
A
, et al. Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
. Am J Transplant
. 2019 Mar 1
;19
(3
):907
–19
. .107.
Morales Febles R, Negrín Mena N, Rodríguez-Rodríguez AE, Díaz Martín L, González Rinne F, Marrero Miranda D, et al. Exercise and Prediabetes after Renal Transplantation (EXPRED): Protocol Description. Nephron. 2021;145(1):55−62.
© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
